Results 1 to 10 of about 14,647 (219)

Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production [PDF]

Cells, 2021
Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. While the use of this reagent has been associated with an increased risk of gastrointestinal bleeding,
Hiromi Kurokawa, Atsushi Taninaka, Hidemi Shigekawa, Hirofumi Matsui   +3 more
doaj   +3 more sources

Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model. [PDF]

Front Pharmacol
Dabigatran etexilate (DABE) is a clinical probe substrate for studying drug-drug interaction (DDI) through an intestinal P-glycoprotein (P-gp). A recent in vitro study, however, has suggested a potentially significant involvement of CYP3A-mediated ...
Udomnilobol U, Dunkoksung W, Sakares W, Jianmongkol S, Prueksaritanont T.   +4 more
europepmc   +4 more sources

Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate. [PDF]

J Thromb Haemost, 2021
Vitamin K antagonists (VKA) and non‐vitamin K oral antagonist anticoagulants (NOAC) are used in the clinic to reduce risk of thrombosis. However, they also exhibit vascular off‐target effects.
van Gorp RH, Dijkgraaf I, Bröker V, Bauwens M, Leenders P, Jennen D, Dweck MR, Bucerius J, Briedé JJ, van Ryn J, Brandenburg V, Mottaghy F, Spronk HMH, Reutelingsperger CP, Schurgers LJ.   +14 more
europepmc   +4 more sources

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. [PDF]

JAMA Neurol, 2019
Key Points Question Is dabigatran etexilate or dose-adjusted warfarin efficacious and safe to use in preventing the recurrence of venous thrombotic events among patients with cerebral venous thrombosis? Findings In this exploratory randomized, open-label
Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, Karpov D, Nagel S, Posthuma L, Roriz JM, Caria J, Frässdorf M, Huisman H, Reilly P, Diener HC, RE-SPECT CVT Study Group.   +15 more
europepmc   +3 more sources

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions [PDF]

Pharmacology Research & Perspectives, 2020
To assess bioequivalence of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions. This was an open‐label, single‐center, randomized four‐period crossover study with a 7‐day washout period. A single oral dose
Xin Li, Lihua Liu, Bing Xu, Qian Xiang, Yuan Li, Ping Zhang, Yangyang Wang, Qiufen Xie, Yong Mao, Yimin Cui   +9 more
doaj   +3 more sources

The Discovery of Dabigatran Etexilate [PDF]

Frontiers in Pharmacology, 2013
Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is caused by an excessive stimulation of coagulation.
Joanne evan Ryn, Ashley M Goss, Norbert eHauel, Wolfgang eWienen, Henning ePriepke, Herbert eNar, Andreas eClemens   +6 more
doaj   +6 more sources

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation. [PDF]

Front Cardiovasc Med, 2022
We aimed to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model from healthy Chinese subjects and real-world non-valvular atrial fibrillation (NVAF) patients.
Liu YO, Xie QF, Liu ZY, Wang Z, Mu GY, Zhang YT, Zhao ZN, Yuan DD, Guo LP, Wang N, Xiang J, Song HT, Jiang J, Xiang Q, Cui YM.   +14 more
europepmc   +2 more sources

Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. [PDF]

J Thromb Haemost, 2021
Dabigatran etexilate (DE), a direct oral thrombin inhibitor, has been evaluated in children with venous thromboembolism (VTE) using oral solution, pellets, or capsules.
Röshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell LG, Bergstrand M, Ibrahim MMA, Joseph D, Tartakovsky I, Gropper S, Brueckmann M, Brandão LR.   +14 more
europepmc   +2 more sources

Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2021
The exposure‐response relationship of direct acting oral anti‐coagulants (DOACs) for bleeding risk is steep relative to ischemic stroke reduction. As a result, small changes in exposure may lead to bleeding events. The overall goal of this project was to
Farhan N, Cristofoletti R, Basu S, Kim S, Lingineni K, Jiang S, Brown JD, Fang LL, Lesko LJ, Schmidt S.   +9 more
europepmc   +2 more sources

Dabigatran Etexilate Related Unilateral Adrenal Hemorrhage. [PDF]

Cureus, 2023
A 63-year-old male presented to our clinic with computed tomography data of a large tumor of the left adrenal gland. The formation is highly suspicious for malignancy with central necrosis and hemorrhage, and a total size of 197/183/201 mm. Due to elevated D-dimer values of 7.17 mg/l (reference range
Kalinov T, Zlatarov A, Kolev N, Ivanov KD.   +3 more
europepmc   +3 more sources